Aptevo Therapeutics Inc. (APVO) Bundle
A Brief History of Aptevo Therapeutics Inc. (APVO)
Foundation and Initial Developments
Aptevo Therapeutics Inc. was founded in 2016 as a spin-off from the biotechnology company Emergent BioSolutions Inc. The company was established to focus on developing innovative therapies for patients with serious diseases. Following its formation, Aptevo began trading on the NASDAQ under the ticker symbol APVO.
Key Products and Developments
Aptevo's lead product, APVO436, is a bispecific T-cell engager designed to target CD3 and CD19 for the treatment of hematologic cancers. The company has also developed other products, including:
- APV-2: A targeted immunotherapy for multiple indications.
- APV-3: A preclinical product with potential applications in immunotherapy.
Financial Overview
As of the end of 2022, Aptevo Therapeutics reported total revenue of $24.1 million, primarily derived from licensing agreements and collaboration partnerships. The company's financial position has been characterized as follows:
| Year | Total Revenue | Net Income (Loss) | Cash and Cash Equivalents | R&D Expenses |
|---|---|---|---|---|
| 2020 | $18.5 million | ($17.0 million) | $12.5 million | $11.9 million |
| 2021 | $15.3 million | ($8.4 million) | $10.1 million | $8.0 million |
| 2022 | $24.1 million | ($7.6 million) | $9.7 million | $6.5 million |
| 2023 (Q2) | $10.2 million | ($3.0 million) | $8.9 million | $4.3 million |
Recent Developments
In 2023, Aptevo announced advancements in its drug candidate APVO436, with upcoming clinical trials slated for initiation in H2 2023. The company has also been actively pursuing partnerships to expand its research capabilities and market reach.
Stock Performance
As of October 2023, Aptevo Therapeutics' stock price stood at approximately $1.15. The stock has experienced volatility, with a 52-week range between $0.88 and $2.30.
Market Position and Competitors
Aptevo Therapeutics operates within a competitive biopharmaceutical landscape, focusing on immunotherapies and targeted treatments. Key competitors include:
- Cellectis S.A.
- Amgen Inc.
- Bristol-Myers Squibb Co.
Future Outlook
Looking forward, Aptevo Therapeutics aims to drive growth through successful clinical trials and strategic collaborations, with the goal of establishing itself as a leader in the immunotherapy sector.
A Who Owns Aptevo Therapeutics Inc. (APVO)
Shareholder Composition
As of the last reported quarter, Aptevo Therapeutics Inc. (APVO) had the following major institutional shareholders:
| Shareholder Name | Ownership Percentage | Number of Shares Held | Type of Ownership |
|---|---|---|---|
| BlackRock, Inc. | 8.04% | 446,000 | Institutional |
| Vanguard Group, Inc. | 6.51% | 362,000 | Institutional |
| State Street Corporation | 5.99% | 332,000 | Institutional |
| Geode Capital Management, LLC | 3.50% | 194,000 | Institutional |
| Wellington Management Co. LLP | 3.45% | 191,000 | Institutional |
Insider Ownership
Insider ownership plays a crucial role in the governance and direction of Aptevo Therapeutics:
| Insider Name | Position | Ownership Percentage | Number of Shares Owned |
|---|---|---|---|
| Marvin L. White | CEO | 1.82% | 100,000 |
| Sheri B. B. Hutton | Chief Financial Officer | 0.75% | 40,000 |
| Ryan D. Scott | Vice President | 0.50% | 25,000 |
Market Capitalization
As of the latest trading session, Aptevo Therapeutics Inc. (APVO) has a market capitalization of:
- Market Cap: $23.5 million
- Current Share Price: $4.00
- 52-Week High: $10.00
- 52-Week Low: $1.50
Recent Stock Performance
Aptevo Therapeutics has shown significant fluctuations in its stock performance:
| Date | Closing Price | Volume | % Change |
|---|---|---|---|
| October 1, 2023 | $4.00 | 100,000 | -4.76% |
| September 1, 2023 | $4.20 | 150,000 | +5.00% |
| August 1, 2023 | $4.00 | 120,000 | -2.44% |
Institutional Investor Trends
The following trends were observed among institutional investors regarding Aptevo Therapeutics:
- Increased holdings by BlackRock, Inc. by 1.5% in the last quarter.
- Vanguard Group, Inc. reduced their stake by 0.5%.
- State Street Corporation maintained their holdings without significant changes.
Financial Overview
Aptevo Therapeutics reported the following financial figures in its most recent earnings report:
| Financial Metric | Amount |
|---|---|
| Total Revenue (Q2 2023) | $2.1 million |
| Net Loss (Q2 2023) | $(5.0) million |
| Total Assets | $15.6 million |
| Total Liabilities | $5.0 million |
Future Outlook
Analysts have made projections regarding Aptevo's future performance:
- Expected revenue growth of 15% annually over the next three years.
- Projected net profit by 2025 if current trends continue.
- Potential partnership opportunities in biotechnology sectors.
Aptevo Therapeutics Inc. (APVO) Mission Statement
Corporate Overview
Corporate Overview
Aptevo Therapeutics Inc. is a biotechnology company focused on developing innovative and differentiated therapeutic options for patients with serious diseases, particularly in the field of oncology and autoimmunity.
Mission Statement
The mission of Aptevo Therapeutics Inc. is to deliver transformative therapies for patients with unmet medical needs through innovative science and pioneering technologies.
Core Values
-
Innovation: Commitment to advancing science.
-
Integrity: Upholding ethical standards in every interaction.
-
Collaboration: Fostering partnerships with stakeholders.
-
Excellence: Striving for the highest quality in product development.
Financial Overview
- Innovation: Commitment to advancing science.
- Integrity: Upholding ethical standards in every interaction.
- Collaboration: Fostering partnerships with stakeholders.
- Excellence: Striving for the highest quality in product development.
Financial Overview
As of the most recent financial reports for the fiscal year ended December 31, 2022, Aptevo Therapeutics reported:
| Financial Metric | 2021 Amount (in millions) | 2022 Amount (in millions) |
|---|---|---|
| Total Revenue | $8.4 | $10.5 |
| Net Loss | ($16.5) | ($12.8) |
| Research and Development Expenses | $13.1 | $9.4 |
| General and Administrative Expenses | $6.5 | $5.6 |
| Cash and Cash Equivalents | $25.0 | $18.2 |
Research and Development Focus
Aptevo Therapeutics emphasizes its R&D efforts on products such as:
- APVO436 - A bispecific therapeutic antibody targeting cancer.
- APVO414 - A T-cell engager for tumor treatment.
- APL-130277 - A treatment for the management of Parkinson’s disease.
Market Position and Objectives
Aptevo aims to position itself within the biotechnology sector by:
- Expanding its pipeline of potential drug candidates.
- Enhancing collaboration with academic and industry partners.
- Increasing market awareness and outreach for its therapeutic innovations.
Recent Developments
In 2023, Aptevo Therapeutics achieved significant milestones:
- Initiation of Phase 2 clinical trials for APVO436.
- Completion of a $15 million financing round to support R&D efforts.
- Partnership established with a leading cancer research institution.
Conclusion of Chapter
The mission statement and corporate ethos of Aptevo Therapeutics Inc. illustrate its dedication to providing innovative therapeutic solutions for patients in need while navigating the complexities of the biotechnology landscape.
How Aptevo Therapeutics Inc. (APVO) Works
Overview of Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. (NASDAQ: APVO) is a biotechnology company that focuses on the development of innovative therapeutic products for immuno-oncology. The company operates mainly in the biopharmaceutical sector, targeting unmet medical needs through its proprietary technology platforms.
Business Model
Aptevo's business model is primarily based on:
- Developing biologic therapies for cancer and autoimmune diseases.
- Leveraging innovative technologies such as the APVO436, an investigational bispecific T-cell engager.
- Forming strategic partnerships and collaborations to enhance its research and development capabilities.
Financial Performance
As of Q3 2023, the financial highlights for Aptevo Therapeutics are as follows:
| Financial Metric | Amount (USD) |
|---|---|
| Revenue (Q3 2023) | $3.4 million |
| Net Loss (Q3 2023) | ($2.1 million) |
| Total Assets (Q3 2023) | $20.5 million |
| Cash and Cash Equivalents (Q3 2023) | $10.7 million |
| Market Capitalization (as of October 2023) | $36.9 million |
Research and Development
The company invests significantly in R&D, focusing on:
- Clinical trials for its lead product candidates.
- Expanding its pipeline through internal and external collaborations.
- Utilizing platforms such as ADAPTIR™ technology for novel therapeutic development.
Partnerships and Collaborations
Aptevo has engaged in various partnerships to enhance its developmental efforts, including:
- Collaboration with leading academic institutions for research.
- Partnerships with other pharmaceutical companies for co-development of therapies.
Market Landscape
Aptevo operates within the immuno-oncology market, projected to reach:
- Approximately $69.3 billion by 2027, growing at a CAGR of 12.2% from 2020.
- Rising demand for advanced therapies targeting cancer.
Key Product Candidates
Important product candidates in development include:
- APVO436: A bispecific T-cell engager currently in clinical trials.
- APVO148: Another candidate focusing on immune modulation.
Stock Performance
As of October 2023, the stock performance metrics are:
| Stock Metric | Value |
|---|---|
| Current Share Price | $2.17 |
| 52-Week Range | $1.50 - $3.75 |
| Volume (last trading day) | 290,000 shares |
| Beta | 1.35 |
Regulatory Landscape
Aptevo's products are subject to stringent regulatory scrutiny by:
- The U.S. Food and Drug Administration (FDA) for clinical trials and approvals.
- The European Medicines Agency (EMA) for European market access.
Future Outlook
Looking forward, Aptevo is focused on:
- Advancing clinical trials for its lead candidates.
- Expanding its research efforts to discover new therapeutic options.
- Strengthening commercial capabilities through potential partnerships.
How Aptevo Therapeutics Inc. (APVO) Makes Money
Revenue Streams
Aptevo Therapeutics Inc. generates revenue through multiple channels, primarily focusing on its biopharmaceutical products, collaborations, and licensing agreements. The company’s leading product is APVO436, designed for treating various hematological malignancies.
Product Sales
Product sales are a significant contributor to Aptevo's revenue. In 2022, Aptevo reported product revenues of approximately $5.9 million, primarily from the sales of their commercialized therapeutic products.
Collaborative and Licensing Agreements
Aptevo enters collaborative agreements with other biotech companies and pharmaceutical firms, providing funding and shared expertise. In fiscal year 2022, the company's revenue from collaborative agreements amounted to $2.3 million, helping to bolster its financial position.
Financial Performance Overview
In the fiscal year 2022, Aptevo's total revenue reached $8.2 million. Here is a summary of the financial performance:
| Year | Total Revenue | Product Revenue | Collaborative Revenue | Net Loss |
|---|---|---|---|---|
| 2022 | $8.2 million | $5.9 million | $2.3 million | ($12.4 million) |
| 2021 | $10.5 million | $7.5 million | $3.0 million | ($11.7 million) |
| 2020 | $9.8 million | $6.8 million | $3.0 million | ($10.5 million) |
Investment and Grants
Additional funding sources include investments and grants. In 2022, Aptevo received $1.5 million in grants and research funding, contributing to its ongoing product development initiatives.
Research and Development (R&D)
Investment in R&D is crucial for Aptevo’s long-term growth. In 2022, R&D expenditures totaled $7.8 million, reflecting the company's commitment to innovation and the development of new therapeutics, which is expected to yield future revenue streams.
Market Capitalization and Stock Performance
As of October 2023, Aptevo Therapeutics' market capitalization stands at approximately $38 million. The company’s stock performance has seen fluctuations, with a share price of around $1.94.
Conclusion of Financial Metrics
Aptevo’s business model is centered around a combination of product sales, collaborations, and continuous investment in R&D, positioning the company for potential future growth in the biopharmaceutical market.
Aptevo Therapeutics Inc. (APVO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support